Scope of the Study
Nocturia is a medical condition in which patients get a frequent urge to urinate while sleeping at night. It is particularly prevalent among the elderly who often find it difficult to sleep properly. It is a common condition experienced by both men and women with profound impact on patient’s health, quality of life, and economic condition. Especially among the elder patients, the lack of sleep often leads to nocturia, it is the most distressing symptoms in older men and women.
The market study is being classified by Type (Nocturnal Polyuria, Bladder Storage Problems and Mixed Nocturia), by Application (Hospitals and Clinics) and major geographies with country level break-up.
Allergan, Inc. (United States), Urigen Pharmaceuticals (United States), Ferring Holding SA (Switzerland), Glenmark Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Avadel Pharmaceuticals (Ireland), Vantia Therapeutics (United Kingdom) and Astellas Pharma Inc. (Japan) are some of the key players profiled in the study.
Companies are focusing on collaboration to develop new more effective products, mergers & acquisitions, expansions, investments. The product type segment of nocturia will be boosted by its higher response rate and increasing research activities for R&D leading to inorganic growth.
Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Nocturia market by Type, Application and Region.
On the basis of geography, the market of Nocturia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Form, the sub-segment i.e. Tablets will boost the Nocturia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Types, the sub-segment i.e. Polyuria will boost the Nocturia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Causes, the sub-segment i.e. Urological Infection will boost the Nocturia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Rise in the prevalence of cardiovascular diseases
Market Trend
- Rising advancements in the drug delivery systems
Restraints
- Undesired systemic effects of treatments
Opportunities
- Increasing investments in the healthcare sector in developing countries
Challenges
- Lack of awareness about the treatments available
Market Leaders and their expansionary development strategies
March 26, 2019: Allergan plc, a leading global pharmaceutical company announced it has completed the acquisition of Envy Medical, Inc., a privately held company with proprietary technology in skin resurfacing. The acquisition enhances Allergan's best-in-class Medical Aesthetics portfolio with the addition of Envy's Dermalinfusion, a non-surgical, non-invasive skin resurfacing system for the face and body. and April 05, 2018: Ferring Pharmaceuticals* and Rebiotix Inc. announced that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.
Key Target Audience
Suppliers of Pharmaceuticals, Wholesalers, Distributers and Retailers Pharmaceuticals, Healthcare Industry, Governmental Bodies and Academic and Government Research Institutes
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase